ABBV-319 engages and activates GR in DLBCL cell lines. (A-C) Immunoblot analysis of GR phosphorylation on serine 211 (S211) and GR expression after treatment with 10 nM GRM and 100 nM ABBV-319 for indicated time in Farage (A), SU-DHL-6 (B), and OCI-LY19 (C). β-actin was used as the loading control. (D) Volcano plot showing the fold change and P value from the meta-analysis of differentially expressed genes (DEGs) between 24-hour ABBV-319 treatment and vehicle control in GRM-sensitive cell lines. Each dot represents a DEG and the selected known GR targets are highlighted in red. (E) Pathways and genes enriched in the meta-analysis of DEGs between the ABBV-319 and vehicle treatment. The color represents the directionality of the fold change, and the size of the circle represents the log(P value). (F) Heat map showing the expression of the 8-gene glucocorticoid gene signature in different immune subsets in PMBC after 24 hours of indicated treatment. (G) Uniform manifold approximation and projection (UMAP) of immune cells within PBMC after the indicated treatment for 24 hours. Color indicates the expression of the 8-gene glucocorticoid gene signature.